Evercore analysts remain skeptical about Caribou's therapy's...

Evercore analysts remain skeptical about Caribou's therapy's competitiveness, planning to wait until 1H 2025 data release. They note the therapy's need for 13 stock products to service 90% of patients will raise COGS, but Caribou team deems it manageable.